Henderson Michael Thomas's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed May 8, 2026
- Accession no.
- 0001636282-26-000053
- Filed
- May 8, 2026
- Trade date
- May 8, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $5.95M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Henderson Michael ThomasCIK 0001779990 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | Common Stock | SSaleDisposed | −2,404 | $72.57 | −$174,458.28 | 166,202 | Direct | |
| May 8, 2026 | Common Stock | SSaleDisposed | −33,513 | $73.72 | −$2,470,578.36 | 132,689 | Direct | |
| May 8, 2026 | Common Stock | SSaleDisposed | −24,814 | $74.76 | −$1,855,094.64 | 107,875 | Direct | |
| May 8, 2026 | Common Stock | SSaleDisposed | −19,269 | $75.35 | −$1,451,919.15 | 88,606 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.